Do antidepressants cause suicidality in children? A Bayesian meta-analysis

Clinical Trials

Volumn 3, Issue 2, 2006, Pages 73-90

  Kaizar, Eloise E ^a   Greenhouse, Joel B ^a,b   Seltman, Howard ^a   Kelleher, Kelly ^c  

^a CARNEGIE MELLON UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANXIETY DISORDER; ARTICLE; BAYES THEOREM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SUICIDAL BEHAVIOR;

ANTIDEPRESSIVE AGENTS; BAYES THEOREM; CHILD; HUMANS; SENSITIVITY AND SPECIFICITY; SUICIDE;

EID: 33744806327     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1191/1740774506cn139oa     Document Type: Article

References (33)

1. Medco press release: Pediatric antidepressant use shows substantial decline over past year. http://www.corporate-ir.net/ireye/irsite.zhtml? ticker=MHS&script=410&layout=-6&item id=668973&sstring=anti depressant, (1 February 2005). Retrieved 10 June 2005.
2. Leslie LK, Newman TB, Chesney J, Perrin JM. The Food and Drug Administration's deliberations on antidepressant use in pediatric patients. Pediatrics 2005; 116: 195-204.
3. Roberts RE, Attkisson CC, Rosenblatt A. Prevalence of psychopathology among children and adolescents. Am J Psychiatry 1998; 155: 715-25.
4. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207-10.
5. Healy D. Let them eat prozac: the unhealthy relationship between the pharmaceutical industry and depression. New York University Press, 2004.
6. Treatment for Adolescents with Depression Study Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 2004; 292: 807-20.
7. Hammad TA. Review and evaluation of clinical data. http://www.fda.gov/ ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf, (August 2004). Retrieved 10 June 2005.
8. Hammad TA. Results of the analysis of suicidality in pediatric trials of newer antidepressants. http://www.fda.gov/ohrms/dockets/ac/04/slides/2004- 4065S1_08_FDA-Hammad.ppt (September 2004). Retrieved 10 June 2005.
9. FDA. Characteristics of pediatric antidepressant trials. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065B1_29_Handout-Tables. pdf, (September 2004). Handout at the September advisory committees meeting. Retrieved 10 June 2005.
10. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. Wiley, 2000.
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7: 177-88.
12. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: A comparative study. Statistics in Medicine 1995; 14: 2685-99.
13. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit (Pkg: P583-639). Journal of the Royal Statistical Society, Series B: Statistical Methodology 2002; 64: 583-616.
14. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian data analysis second edition. Chapman and Hall/CRC, 2003.
15. Warn DE, Thompson SG, Spiegelhalter DJ. Bayesian random effects meta-analysis of trials with binary outcomes: methods for absolute risk difference and relative risk scales. Statistics in Medicine 2002; 21: 1601-23.
16. Dempster AP, Rubin DB, Tsutakawa RK. Estimation in covariance components models. Journal of the American Statistical Association 1981; 76: 341-53.
17. Gilks WR, Thomas A, Spiegelhalter DJ. A language and program for complex Bayesian modelling. The Statistician: Journal of the Institute of Statisticians 1994; 43: 169-77.
18. DuMouchel W. Hierarchical Bayes linear models for meta-analysis. Tech. Rep. 27, National Institute of Statistical Sciences, September 1994.
19. Greenhouse JB, Seltman H. Using prior distributions to synthesize historical evidence: Comments on the Goodman-Sladky case study of IVIg in Guillan-Barré syndrome. Clinical Trials: Journal of the Society for Clinical Trials 2005; 2: 311-18.
20. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. Wiley, 2004.
21. Chaloner K. Elicitation of prior distributions. In Berry D, Stangl D eds. Bayesian biostatistics. Marcel Dekker, 1996: 141-56.
22. Garthwaithe PH, Kadane JB, O'Hagan A. Statistical methods for eliciting probability distributions. Journal of the American Statistical Association 2005; 100: 680-700.
23. Kass RE, Greenhouse JB. Comments on "Investigating therapies of potentially great benefit: ECMO". Statistical Science 1989; 4: 310-17.
24. Agresti A. Categorical data analysis. John Wiley & Sons, 1990: 462-64.
25. Lieberman JA, Greenhouse JB, Hamer R et al. Comparing the effects of antidepressants: Consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 2005; 30: 445-60.
26. Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the CDER psychopharmacologic drugs advisory committee and the FDA pediatric advisory committee. http://www. fda.gov/ohrms/dockets/ac/04/ minutes/2004-4065M1_ Final.doc, (September 2004). Retrieved 10 June 2005.
27. Iyengar S, Greenhouse J. Selection models and the file-drawer problem. Statistical Science 1988; 3: 109-17.
28. Rosenthal R. The "file-drawer problem" and tolerance for null results. Psychological Bulletin 1979; 86: 638-41.
29. Young EA, Coryell W. Suicide and the hypothalamic-pituitary-adrenal axis. Lancet 2005; 366: 959-61.
30. Gibbons RD, Hur K, Bhawnik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Archives of General Psychiatry 2005; 62: 165-72.
31. Brent DA. Antidepressants and pediatric depression - the risk of doing nothing. New England Journal of Medicine 2004; 351: 1598-601.
32. Greenhouse J, Kelleher K. Thinking outside the (black) box: Antidepressants, suicidality and research synthesis. Pediatrics 2005; 116: 231-233.
33. Cornfield J. Recent methodological contributions to clinical trials. American Journal of Epidemiology 1976; 104: 408-21.